{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-2.3","upperLimit":"-0.8","value":"-1.5"},{"groupId":"OG001","lowerLimit":"-1.0","upperLimit":"0.6","value":"-0.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"382"},{"groupId":"OG001","value":"359"}],"units":"Participants"}],"title":"Change from baseline FACIT-Fatigue Score to 6 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-2.4","upperLimit":"-0.6","value":"-1.5"},{"groupId":"OG001","lowerLimit":"-0.9","upperLimit":"0.9","value":"0.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"382"},{"groupId":"OG001","value":"356"}],"units":"Participants"}],"title":"Change from baseline FACIT-Fatigue Score to 12 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.4","upperLimit":"2.2","value":"1.3"},{"groupId":"OG001","lowerLimit":"0.5","upperLimit":"2.3","value":"1.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"382"},{"groupId":"OG001","value":"359"}],"units":"Participants"}],"title":"Change from baseline FACIT-Fatigue Score to 18 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.7","upperLimit":"2.4","value":"1.6"},{"groupId":"OG001","lowerLimit":"1.1","upperLimit":"2.9","value":"2.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"382"},{"groupId":"OG001","value":"359"}],"units":"Participants"}],"title":"Change from baseline FACIT-Fatigue Score to 24 months"}],"denoms":[{"counts":[{"groupId":"OG000","value":"382"},{"groupId":"OG001","value":"359"}],"units":"Participants"}],"description":"Change from baseline for FACIT-Fatigue Score at 6, 12, 18 and 24 months for patients who completed neoadjuvant chemotherapy. Adjusted least-square mean changes and 95% Confidence Interval (CI) are obtained from mixed model for repeated measures (MMRM) analysis of the change from baseline. Only patients with evaluable baseline forms are included. FACIT-Fatigue score ranges from 0 to 52 with higher score indicating less fatigue.","dispersionType":"95% Confidence Interval","groups":[{"description":"Olaparib tablets 300mg taken orally twice daily.","id":"OG000","title":"Olaparib"},{"description":"Placebo tablets taken orally twice daily.","id":"OG001","title":"Placebo"}],"paramType":"MEAN","populationDescription":"Patient reported outcomes (PRO) Analysis Set","reportingStatus":"POSTED","timeFrame":"6, 12, 18 and 24 months after randomisation (data cut off: 12 July 2021)","title":"Change From Baseline for FACIT-Fatigue (Functional Assessment of Chronic Illness Therapy-Fatigue) Score for Participants Who Completed Neoadjuvant Chemotherapy","type":"SECONDARY","unitOfMeasure":"Scores on a scale"}